通过母乳接触心理药物:丹麦一项基于人口的描述性研究
Xiaoqin Liu1, Kathrine Bang Madsen1,2, Jin Liang Zhu1
1NCRR-The National Centre for Register-Based Research, Department of Public Health, Aarhus University, Aarhus, Denmark.
Paediatric and perinatal epidemiology
|September 11, 2025
概括
丹麦约有2%的纯母乳养婴儿通过母乳接触到精神药物. 这种暴露,特别是抗抑郁药,在2012年至2022年期间显示出显著的上升趋势.
科学领域:
- 围产期药理学 围产期药理学
- 婴儿健康 婴儿健康
- 精神病药物的安全性 精神病药物的安全性
背景情况:
- 有限的数据存在于通过母乳传递给婴儿的精神药物药物传递.
- 了解婴儿暴露对于临床实践和研究至关重要.
- 这项研究解决了对母乳养婴儿心理药物暴露的数据需求.
研究的目的:
- 确定纯母乳养婴儿中心理药物暴露的流行率和趋势.
- 根据药物类别和母性因素分析暴露模式.
- 为医疗保健提供者和研究人员提供必要的数据.
主要方法:
- 基于人口的描述性研究,使用丹麦全国性注册表 (2012-2022年).
- 在母乳养期间确定的母性精神药物处方 (ATC代码N05-N06).
- 每1000名婴儿计算的患病率,按药物类别和母亲特征分层.
主要成果:
- 研究了超过446,000名婴儿;每1000名婴儿中,有17.6名婴儿至少服用了一种精神药物.
- 抗抑郁药 (15.0/1000),主要是塞特拉林,是最常见的暴露.
- 暴露量从2012年 (15.7/1000) 到2022年 (21.8/1000) 增加了39%,其中精神兴奋剂的暴露量显著增加.
结论:
- 在丹麦,大约2%的纯母乳养婴儿可能会接触到心理药物.
- 在研究期间观察到心理药物暴露的明显上升趋势.
- 患病率因母亲的人口统计和临床因素而异,突出显示需要个性化风险评估.
相关概念视频
Pharmacovigilance
2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
928
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
928
Therapeutic Drug Monitoring: Affecting Factors
429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
967
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect
266
The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
266
Development of Human Microbiota
61
The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from...
61


